Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma

Torben Plesner, Hendrik-Tobias Arkenau, Peter Gimsing, Jakub Krejcik, Charlotte Lemech, Monique C. Minnema, Ulrik Lassen, Jacob P. Laubach, Antonio Palumbo, Steen Lisby, Linda Basse, Jianping Wang, A. Kate Sasser, Mary E. Guckert, Carla de Boer, Nushmia Z. Khokhar, Howard Yeh, Pamela L. Clemens, Tahamtan Ahmadi, Henk M. LokhorstPaul G. Richardson

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)1821-1828
JournalBlood
Volume128
Issue number14
DOIs
Publication statusPublished - 6 Oct 2016

Cite this

Plesner, T., Arkenau, H-T., Gimsing, P., Krejcik, J., Lemech, C., Minnema, M. C., ... Richardson, P. G. (2016). Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma. Blood, 128(14), 1821-1828. https://doi.org/10.1182/blood-2016-07-726729